Skip to content
DEALDATABASEby Legal Desire
14 December 2023

Freshfields Advising AstraZeneca on $1.1bn Icosavax Acquisition

Advising firms

Deal team

19 lawyers named
LawyerFirmSeniorityPracticeOffice
Sebastian Fain Lead Freshfields Partner M&A Not stated
Oliver Board Freshfields Counsel M&A Not stated
Arash Ardalan Freshfields Senior associate M&A Not stated
Kelsey MacElroy Freshfields Senior associate M&A Not stated
Connor Smith Freshfields Associate M&A Not stated
Vinita Kailasanath Freshfields Partner life sciences Not stated
Sora Park Freshfields Associate life sciences Not stated
Jake Silvers Freshfields Associate life sciences Not stated
Madeleine Tavcar Freshfields Associate life sciences Not stated
Nicole Foster Freshfields Partner executive compensation and employee benefits Not stated
Jordan Salzman Freshfields Counsel executive compensation and employee benefits Not stated
Lina Zhu Freshfields Associate executive compensation and employee benefits Not stated
Mary Lehner Freshfields Partner antitrust Not stated
Jenny Leahy Freshfields Partner antitrust Not stated
Simon Priddis Freshfields Partner antitrust Not stated
Laura Onken Freshfields Counsel antitrust Not stated
Remony Vials Freshfields Associate antitrust Not stated
Claude Stansbury Freshfields Partner tax Not stated
Hannah Golden Freshfields Associate tax Not stated

Stated terms

Stated value
USD 1.10bn ($1.1bn)
What the figure measures
Total transaction value
Client
AstraZenecaBuy-side
Counterparties
Icosavax (Target)